Company Description
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel.
It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson’s syndrome, and toxic epidermal necrolysis.
The company also provides contract development and manufacturing organization services to biotech companies.
It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody.
The company has a strategic collaboration with Recipharm Israel Ltd for the development of Lifecycle CDMO Platform.
The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023.
Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
| Country | Israel |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Amir Reichman |
Contact Details
Address: Jerusalem BioPark, 2nd floor Jerusalem Israel | |
| Phone | 972 8 930 2529 |
| Website | scinai.com |
Stock Details
| Ticker Symbol | SCNI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001611747 |
| CUSIP Number | 09073Q204 |
| ISIN Number | US09073Q3039 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Amir Reichman M.B.A., M.Sc. | Chief Executive Officer and Director |
| Uri Ben-Or C.P.A., M.B.A. | Chief Financial Officer |
| Elad Mark B.Sc., Eng., M.B.A. | Chief Operating Officer |
| Gal Ron | Head of Human Resources |
| Merav Kamensky | Head of Quality Control and GMP Analytics |
| Dr. Naama Adi Hen | Head of Quality Asurance |
| Tehila Sonnenfeld | Head of Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | 6-K | Report of foreign issuer |
| Apr 1, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 23, 2026 | 6-K | Report of foreign issuer |
| Mar 19, 2026 | 6-K | Report of foreign issuer |
| Feb 25, 2026 | 6-K | Report of foreign issuer |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | 6-K | Report of foreign issuer |
| Dec 23, 2025 | 6-K | Report of foreign issuer |
| Dec 2, 2025 | 6-K | Report of foreign issuer |
| Nov 13, 2025 | 6-K | Report of foreign issuer |